ADHD and Telehealth in 2026: What the Extended Federal Prescribing Flexibilities Mean for Patients

Why this matters for people with ADHD

Attention-deficit/hyperactivity disorder (ADHD) affects millions of children and adults in the United States. According to the Centers for Disease Control and Prevention (CDC), ADHD is one of the most common neurodevelopmental disorders of childhood, and many people continue to have symptoms into adulthood. Stimulant medications such as methylphenidate and amphetamine products are a core part of treatment for many patients.

Those medications are classified as Schedule II controlled substances under federal law. That classification reflects both their medical value and their potential for misuse. It also means they are subject to strict prescribing rules under the Controlled Substances Act.

During the COVID-19 public health emergency, federal agencies temporarily allowed clinicians to prescribe certain controlled substances via telehealth without first conducting an in-person visit. For many people with ADHD—especially those in rural areas or those relying on virtual psychiatry—that flexibility became a critical part of staying in treatment.

In late 2024, the U.S. Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS) formally extended those telemedicine flexibilities through December 31, 2025, as documented in a joint announcement and an official rule published in the Federal Register.

Now, in March 2026, patients and families need to understand what that extension covered, what is clear, what may still be evolving, and how to avoid gaps in care.

What the federal extension allowed through December 31, 2025

Under pre-pandemic rules, the Ryan Haight Online Pharmacy Consumer Protection Act generally required an in-person medical evaluation before a clinician could prescribe a Schedule II controlled substance.

During the COVID-19 emergency, federal agencies waived that in-person requirement for certain telemedicine encounters. The 2024 DEA and HHS action extended those flexibilities through December 31, 2025. According to the DEA and HHS announcements and the Federal Register rule:

DEA-registered clinicians could prescribe certain Schedule II–V controlled substances via telemedicine without a prior in-person exam, if specific conditions were met.
Telemedicine visits had to be conducted using real-time, two-way audio-video communication technology.
Clinicians still had to comply with all other federal and state laws, including state licensure requirements.

The extension did not permanently rewrite the Controlled Substances Act. It temporarily maintained the pandemic-era flexibility while DEA worked toward a long-term regulatory framework.

Where things stand in March 2026

The key fact is this: the formal extension described by DEA and HHS had a defined end date of December 31, 2025.

As of March 20, 2026, patients should not assume that the same nationwide telehealth prescribing rules automatically remain in place. Federal policy may have been updated, replaced, or allowed to expire. Long-term regulations have been under discussion for several years, and details can change.

If you or your child receives stimulant medication for ADHD via telehealth, it is important to:

Confirm with your prescribing clinician what federal rules currently apply.
Check for any new DEA regulations or guidance.
Understand that requirements may differ depending on when your treatment relationship began.

This is not just a legal technicality. If an in-person visit becomes required and you are not prepared, prescriptions could be delayed.

How federal, state, and pharmacy rules interact

Even when federal flexibilities were in effect, they were only one piece of the puzzle.

State licensure laws: In general, clinicians must be licensed in the state where the patient is physically located during the telehealth visit. A psychiatrist licensed in one state cannot automatically prescribe to a patient who is temporarily in another state.

State telehealth rules: Some states have additional requirements for telemedicine encounters, documentation, or controlled substance prescribing.

Pharmacy policies: Pharmacies may have their own verification steps, especially for Schedule II stimulants. During national stimulant shortages in recent years, some pharmacies required additional documentation or limited transfers between locations.

Insurance coverage: Private insurers, Medicaid, and employer plans may have specific telehealth coverage rules. Even if federal law permits telehealth prescribing, an insurer may require periodic in-person visits for continued coverage.

In practice, that means a telehealth prescription can be legal under federal rules but still run into obstacles at the state, insurance, or pharmacy level.

Who may be most affected

Rural patients: People living far from psychiatrists or pediatric specialists often rely on telehealth to maintain ADHD treatment.

College students: Students who move across state lines for school may discover their clinician is not licensed where they are physically located.

Children in shared custody: If a child splits time between two states, prescribing rules can become more complicated.

Virtual-only psychiatry practices: Some practices were built around pandemic-era telehealth rules. Any regulatory tightening could require operational changes.

These groups are at higher risk of care disruption if rules shift or if documentation requirements increase.

Practical steps to prevent treatment gaps

If you or your child takes a Schedule II stimulant for ADHD, consider these steps in 2026:

Schedule follow-ups early. Do not wait until the last week of medication to request a refill.
Ask your clinician directly whether any new federal or state requirements apply to you.
Confirm your physical location rules. If you travel or relocate, check whether your clinician is licensed in that state.
Keep documentation organized. Pharmacies may request confirmation of diagnosis or prescriber credentials.
Monitor official sources. DEA, HHS, and SAMHSA regularly publish updates about telehealth and controlled substances.

For families with children, coordination with pediatricians, schools, and mental health providers can help reduce the risk of missed doses that affect learning or behavior.

What to watch for next from DEA and HHS

Federal agencies signaled that the 2025 extension was temporary while permanent telemedicine prescribing rules were being developed. Any final rule would likely be published in the Federal Register and announced by DEA and HHS.

Patients should watch for:

Clear guidance on whether an initial in-person visit is required.
Any special registration pathways for telemedicine providers.
Changes in documentation or recordkeeping requirements.

Until permanent rules are clearly established, the safest approach is proactive communication with your prescriber and pharmacy.

The bottom line

Stimulant medications for ADHD are Schedule II drugs, and federal law tightly regulates how they can be prescribed. DEA and HHS extended pandemic-era telehealth flexibilities through December 31, 2025, allowing certain controlled substances to be prescribed without a prior in-person visit under defined conditions.

As of March 2026, patients should confirm what rules currently apply. Federal, state, insurance, and pharmacy policies all intersect, and changes can affect access.

For families and adults managing ADHD, planning ahead—early appointments, license checks, refill timing, and monitoring official updates—can make the difference between continuity of care and an avoidable treatment interruption.

Staying informed is not just about compliance. For many people with ADHD, consistent access to medication supports school performance, workplace stability, driving safety, and daily functioning. Clear communication now can prevent unnecessary stress later.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.